Login to Your Account


Regado anticoagulant's phase III clog: DSMB eyes allergic reaction threat

By Randy Osborne
Staff Writer

Thursday, July 3, 2014
Regado Biosciences Inc.'s double-punch anticoagulant took one on the chin from Wall Street, as investors learned about an unplanned review by the data safety monitoring board (DSMB) of the phase III trial testing the drug previously known as REG1 in patients undergoing percutaneous coronary intervention (PCI).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription